The Medical Letter - 2009
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:      2009 Annual Index: U.S. English | Canadian English
January 12, 2009 (Issue 1303)  
  • Long-Acting Beta-2 Agonists in Asthma   
    Continued use of a long-acting beta-2 agonist for treatment of asthma may cause down-regulation of the beta-2 receptor with loss of the bronchoprotective effect from rescue therapy with a...
  • PPI Interactions with Clopidogrel   
    Clopidogrel (Plavix), which prevents arterial thrombosis by inhibiting platelet activation, is commonly prescribed (usually with aspirin) for months after acute coronary syndromes and stent...
  • Silodosin (Rapaflo) for Benign Prostatic Hyperplasia   
    Silodosin (Rapaflo - Watson Pharmaceuticals), an alpha1a-adrenoreceptor selective antagonist, has been approved by the FDA for treatment of benign prostatic hyperplasia (BPH). Some...
  • Correction: CT Colonography   
    (Med Lett Drugs Ther 2008; 50:94) In Table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively. In the conclusion, CT colonography...
January 26, 2009 (Issue 1304)  
February 9, 2009 (Issue 1305)  
February 23, 2009 (Issue 1306)  
March 9, 2009 (Issue 1307)  
March 23, 2009 (Issue 1308)  
  • Dexlansoprazole (Kapidex) for GERD and Erosive Esophagitis   
    The FDA has approved the proton-pump inhibitor (PPI) dexlansoprazole (Kapidex - Takeda), a delayed release formulation of the R-enantiomer of lansoprazole (Prevacid - Takeda), for...
  • Focalin XR for ADHD   
    Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which...
  • In Brief: Different Diets   
    A recent article in the New England Journal of Medicine confirms something that others, including The Medical Letter (Treat Guidel Med Lett 2008; 6:23), have been saying for years: no particular...
April 6, 2009 (Issue 1309)  
April 20, 2009 (Issue 1310)  
May 4, 2009 (Issue 1311)  
May 18, 2009 (Issue 1312)  
June 1, 2009 (Issue 1313)  
June 15, 2009 (Issue 1314)  
June 29, 2009 (Issue 1315)  
July 13, 2009 (Issue 1316)  
July 27, 2009 (Issue 1317)  
August 10, 2009 (Issue 1318)  
  • Tapentadol (Nucynta) - A New Analgesic   
    The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule...
  • Tablet Splitting   
    Superseded by The Medical Letter "Tablet Splitting" - Issue 1396, August 6, 2012Readers have asked us to update our 2004 article on tablet splitting. Breaking drug tablets in half is a common...
  • In Brief: Heat and Transdermal Fentanyl   
    Transdermal fentanyl (Duragesic, and others) offers a convenient delivery system for patients with chronic pain1 but it has some drawbacks. One is that exposing the patch to heat, either...
August 24, 2009 (Issue 1319)  
  • Safety of Smoking Cessation Drugs   
    The most effective drugs available for treatment of tobacco dependence are bupropion (Zyban, and others and varenicline (Chantix). The FDA recently ordered the manufacturers of both to...
  • A New Japanese Encephalitis Vaccine (Ixiaro)   
    The FDA has approved a new Japanese encephalitis vaccine (Ixiaro - Intercell/Novartis). It will replace JEVax (Sanofi Pasteur), which has had tolerability and safety problems and is no...
  • Insulin Glargine (Lantus) and Cancer Risk   
    Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.
  • Corrections   
    Benzyl Alcohol Lotion for Head Lice (Med Lett Drugs Ther 2009; 51:57) In Table 1, the price for lindane 1% shampoo should be $136.86 (not $3.00). When a Statin...
September 7, 2009 (Issue 1320)  
September 21, 2009 (Issue 1321)  
October 5, 2009 (Issue 1322)  
October 19, 2009 (Issue 1323)  
  • Generic Drugs Revisited   
    The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic...
  • Degarelix (Firmagon) for Prostate Cancer   
    The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced...
  • Recombinant Human Antithrombin (ATryn)   
    The FDA has approved the use of recombinant human antithrombin (rhAT; ATryn - Lundbeck) in patients with inherited antithrombin (AT) deficiency to prevent thrombosis during or after surgery...
November 2, 2009 (Issue 1324)  
November 16, 2009 (Issue 1325)  
  • Antiviral Drugs for Influenza   
    Superseded by The Medical Letter "Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza" - Issue 1563, January 14, 2019Currently circulating influenza virus is almost...
November 30, 2009 (Issue 1326)  
December 14, 2009 (Issue 1327)